Fate Therapeutics (FATE) Stock Price, News & Analysis

Company Overview

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $2.15 to $2.56
• 50-Day Range: $2.17 to $4.02
• 52-Week Range: $2.05 to $8.83
• Volume: 1.76 million shs
• Average Volume: 2.18 million shs
• Market Capitalization: $247.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.89
• Consensus Rating: Hold

Fate Therapeutics Stock Analysis - MarketRank™

Fate Therapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 195th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Fate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 4 buy ratings, 6 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Fate Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Fate Therapeutics are expected to grow in the coming year, from ($1.73) to ($1.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fate Therapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fate Therapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fate Therapeutics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.96% of the outstanding shares of Fate Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Fate Therapeutics has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Fate Therapeutics has recently decreased by 1.00%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fate Therapeutics does not currently pay a dividend.

Dividend Growth

Fate Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.70

Percentage of Shares Shorted

13.96% of the outstanding shares of Fate Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Fate Therapeutics has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Fate Therapeutics has recently decreased by 1.00%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.29

News Sentiment

Fate Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Fate Therapeutics this week, compared to 4 articles on an average week.

Search Interest

1 people have searched for FATE on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fate Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.00% of the stock of Fate Therapeutics is held by insiders.

Percentage Held by Institutions

97.54% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FATE Stock Analysis - Frequently Asked Questions

How have FATE shares performed this year?

Fate Therapeutics' stock was trading at $3.74 on January 1st, 2024. Since then, FATE stock has decreased by 42.0% and is now trading at $2.17.
View the best growth stocks for 2024 here.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) announced its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.02. The biopharmaceutical company earned $3.07 million during the quarter, compared to analyst estimates of $0.88 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 44.88% and a negative net margin of 1,325.43%.

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (2.14%), Charles Schwab Investment Management Inc. (0.67%), FMR LLC (0.20%) and BNP Paribas Financial Markets (0.15%). Insiders that own company stock include Redmile Group, Llc, J Scott Wolchko, John Mendlein, Bahram Valamehr, Cindy Tahl, Yu-Waye Chu, Mark Plavsic, Edward J Dulac III, Brian T Powl and Yuan Xu.
View institutional ownership trends.

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Fate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fate Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Meta Platforms (META), Alibaba Group (BABA) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 11/13/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/24/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FATE
• CUSIP: N/A
• CIK: 1434316
• Web: www.fatetherapeutics.com
• Phone: (858) 875-1800
• Fax: N/A
• Employees: 550
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.89
• High Stock Price Target: $10.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +217.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.27
• Research Coverage: 11 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-160,930,000.00
• Net Margins: -1,325.43%
• Pretax Margin: -1,426.67%
• Return on Equity: -44.88%
• Return on Assets: -33.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.18
• Quick Ratio: 9.18

Sales & Book Value

• Annual Sales: $63.53 million
• Price / Sales: 3.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.74 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 113,880,000
• Free Float: 108,184,000
• Market Cap: $247.12 million
• Optionable: Optionable
• Beta: 1.88